KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Changes in frailty based on minimally important difference and the impact of spironolactone on frailty in heart failure with preserved ejection fraction: insights from the TOPCAT trial.

Yangyang Tang, Wenjie Li, Zhiyan Wang, Shuk Han Chu, Yanfang Wu, Zhaoxu Jia, Chang Hua, Hao Zhang, Xinru Liu, Qiang Lv, Chao Jiang, Jian-Zeng Dong, Chang-Sheng Ma, Xin Du

Open Heart 12(2) e003487

PMID41125402
PMCIDPMC12548596
DOI10.1136/openhrt-2025-003487
发表日期2025-10-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: The minimally important difference (MID) for frailty variation associated with adverse outcomes remains unknown in patients with heart failure and preserved ejection fraction (HFpEF), and whether spironolactone can ameliorate frailty progression in this population remains unclear. METHODS: We analysed data from 1767 participants in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. The MID for frailty was calculated using an anchor-based approach, with the EuroQol-Visual Analogue Scale (EQ-VAS) as the anchor. Frailty index (FI), defined as a 35-item cumulative deficit score, and EQ-VAS were assessed at baseline and 1-year follow-up. The primary composite outcome (cardiovascular death, aborted cardiac arrest or heart failure hospitalisation) was assessed from the 1-year follow-up visit. Adjusted Cox proportional hazards models evaluated the link between FI changes (ΔFI≥MID) and the primary outcome. Longitudinal FI changes were analysed using linear mixed-effects models to evaluate spironolactone's effect. RESULTS: The MID for the FI was 0.03 points. An FI reduction ≥MID was associated with a lower risk of the primary composite outcome (aHR, 0.63; 95% CI 0.48 to 0.82), all-cause mortality (aHR, 0.57; 95% CI 0.42 to 0.76) and heart failure hospitalisation (aHR, 0.55; 95% CI 0.40 to 0.75) after adjusting for baseline FI, age, sex, New York Heart Association class, smoking status and treatment assignment. No between-group difference in FI change was observed with spironolactone versus placebo (aOR, 0.85; 95% CI 0.67 to 1.09). CONCLUSIONS: Frailty improvement exceeding the 0.03 FI threshold predicts better prognosis in HFpEF, underscoring the value of routine assessment. Spironolactone use was associated with neutral effects on frailty progression in our analysis, suggesting potential safety in this vulnerable population. TRIAL REGISTRATION NUMBER: NCT00094302.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2. Kaplan-Meier estimation of adverse outcomes by FI change groups. The primary outcome was a composite of cardiovascular mortality, aborted cardiac arrest and heart failure hospitalisation. Models adjusted for baseline FI, age, sex, New York Heart Association and smoking. FI, frailty index; HF, heart failure.

Primary_Outcomes

Primary Outcome

Figure 2 · Panel Primary_Outcomes

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Primary_Outcomes 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:off origin start曲线 2:off origin start
查看结果
All-Cause_Mortality

All-Cause Mortality

Figure 2 · Panel All-Cause_Mortality

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel All-Cause_Mortality 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
HF_hospitalization

HF hospitalization

Figure 2 · Panel HF_hospitalization

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel HF_hospitalization 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Distribution of patients into EQ-VAS categories. The figure shows the number of patients for each of the EQ-VAS categories. EQ-VAS, EuroQol-Visual Analogue Scales; FI, frailty index.
非 KM Figure
Figure 3Figure 3. The frailty index at every visit in each group. FI, frailty index.
非 KM Figure